Atopic and non-atopic eczema is an inflammatory cutaneous disease which is common in childhood and is associated with a dysregulation of the immune system. Many genes encoding immune receptors, cytokines, chemokines, chemokine receptors, and adhesion molecules involved in the development of the disease are under the control of transcription factors belonging to the nuclear factor (NF)-KB family. To investigate the role of NF-KB in the development of eczema, 20 children, affected by relapsing chronic eczema, were enrolled in this study. Eleven of the 20 children showed IgE immunoreactivity and had a positive prick test. The DNA binding activity of NF-KB in nuclear extracts of the patients' peripheral blood mononuclear cells (PBMC) was examined by electrophoretic mobility shift assay. We found that basal NF-KB-DNA binding activity in PBMC was significantly higher in the eczema patient group in comparison with the same parameter in the healthy age-matched control group. Moreover, we observed a significant correlation between NF-KB-DNA binding activity and patients' clinical score (SCORAD). Based on these observations we speculate that NF-KB can play an important role in the immunopathogenesis of eczema and therefore could be considered as a potential therapeutic target.
cRel, Rei A (P65) and Rei B (6) . NF-KB is retained in the cytoplasm in its inactive form by interaction with various inhibitors known as IKBs. Modification of IKB in response to a variety of pro-inflammatory signals, leads to the translocation of NF-KB subunits from the cytoplasm to the nucleus where they activate their target genes upon binding to their consensus sequences. The most common form of NF-KB is a heterodimer consisting of p50 and p65 subunits, which can form different complexes in response to specific stimuli, thus allowing for different DNA-binding specificities and trans activation potentials (7) .
Whether NF-KB is directly involved in the pathogenesis of eczema has not yet been demonstrated, but several lines of evidence suggest that it may play a pivotal role in the skin inflammation which is characteristic of the disease. NF-KB is probably a crucial factor for the recruitment of activated lymphocytes to the site of skin inflammation since it controls the transcription of chemoattractants, such as eotaxin, IL-5, MCP-I, MIP-l, RANTES, and MCP-4, chemokine receptors, such as CCR3, and adhesion molecules such as ICAM-l, F-selectin, and VCAM-l (8) (9) .
An important feature of eczema is that Th 1 and Th2 cytokines are involved in the pathogenesis of cutaneous inflammation, and their specific expression varies in different phases ofthe disease. In acute eczema, infiltrating T cells are responsible for increased IL-4 and IL-13 expression, while chronic inflammation is characterized by the prominent production of IL-5, GM-CSF, IL-12 and IFN-y. The transcription of all these cytokines is mediated by NF-KB (10) (11) . In particular, the over-expression of IL-12 contributes to the promotion of the switch to the Th I cytokine profile typical of chronic eczema (12) . Although NF-KB has been hitherto considered as mediator of acute inflammatory responses, it has been shown to be persistently activated also in chronic inflammatory conditions such as inflammatory arthritis (13) , inflammatory bowel diseases (14) , atherosclerosis (15) , asthma (16) (17) , and, more recently, also in psoriasis (18-20) and eczema (21) .
The observation that some pro-inflammatory cytokines involved in anergic response, such as TNF-u, are regulated by NF-KB and can themselves activate NF-KB expression, indicates that a feed-forward amplification loop exists that could form the basis for the persistence of chronic inflammatory processes in eczema (2, 12) . Furthermore, interesting work performed on animal models of allergic asthma (22) (23) (24) and cutaneous inflammation (25) (26) (27) supports the idea that NF-KB plays a pivotal role in the induction and maintenance of the skin inflammation in eczema. To investigate the potential role of NF-KB in the pathogenesis of eczema we studied NF-KB-DNA binding activity in peripheral blood mononuclear cells (PBMC) of children affected by chronic atopic and non-atopic eczema.
MATERIALS AND METHODS

Patients
Twentychildren (12 male and 8 female, aged between 6 and 144 months, mean 51.6, median 28.5), affected by relapsing chronic eczema for at least 6 months, were enrolled in this study. Eleven children out of 20 (55%) showed detectable IgE sensitization and positive prick test. Twelve out of 20 (60%) were suffering from mildmoderate eczema (SCORAD ranging between 10 and 25) and 8 out of20 (40%) from severeeczema (SCORADover 25). The characteristics of the patients are summarized in Table I . At the time of the enrolment no patient had been taking either local or oral antibiotics or corticosteroids or immunosuppressive drugs for at least 2 weeks.
Three patients (p I, p5 and p20), who were affected by severeeczemarefractorytoconventionalspecifictherapies, underwent therapy with intravenous methylprednisolone bolus (20 mg/Kg/die) for 3 consecutive days (28), as inpatients. As control group, nine age-matched children were included in the study, 5 male and 4 female, aged between 2 and 168 months (mean 68.7, median 30), with neither family history nor clinical symptoms of allergy, and negative for skin prick test and serum IgE.
SCORAD
The severity of eczema was evaluated using the SCORAD Index (27) . This index consists of several evaluation criteria (objective and subjective) of variable weight, giving a global quantitative score representing the intensity of disease at a given time. The objective criteria include the extent and intensity of the disease. The subjective signs assess the itching and sleep loss related to eczema.
Serum IgE quantitation
Serum samples were blind-coded prior to the quantitation of IgE. IgE specific for inhalant and food allergens were tested with Pharmacia RAST according to the manufacturer's instructions. Titers were expressed as IU/ml.
Cells
Peripheral blood mononuclear cells (PBMC) were obtained from patients and healthy donors by gradient centrifugation over Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden). A minimum of IOxlO 6 cells was lysed immediately after separation. Reference PBMC obtained from adult healthy donors were cultured with or without PHA (5 ug/ml) (Sigma, St Louis, MO, U.S.A) for 1 hr before lysis.
Nuclear extracts
Nuclear extracts were prepared according to Andrews et al. (30) . Briefly, cells were lysed in 400 j.11 of buffer A (10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCI2, 10 mM KCI, 0.5 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PM SF) and protease inhibitors for 15 min on ice. After centrifugation at 1,000 rpm for I min at 4°C, the nuclear pellet was lysed with 30-50 j.11 of buffer C (HEPES-KOH 20 mM, pH 7.9, 25% glycerol, 420 mM NaCI, 1.5 mM MgCI2, 0.2 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors for 20 min on ice. Following centrifugation at 12,000 rpm for 10 min, supernatants were harvested and protein concentration was determined (Bio-Rad protein assay). All reagents were obtained from Sigma (St Louis, MO, U.S.A).
Electrophoretic Mobility Shift Assay (EMSA)
The DNA binding activity of NF-KB was examined by EMSA using Lightshift chemioluminescent EMSA kit (Pierce Chemical Company, Rockford, USA). Briefly, for each binding reaction 30 fmol of biotin end-labeled double-stranded KB oligonucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3 ') (Invitrogen, Groningen, Netherlands) was incubated with 6 ug of nuclear extract obtained from patient or control PBMC in binding buffer in the presence of 1 ug poly(dI-dC) as nonspecific competitor. The reaction mixture was incubated for 15 min at RT and loaded on 5% not denaturing polyacrylamide (29: 1 acrylamide: bisacrylamide) gel in 0.5x tris-borate-EDTA (TBE) buffer. The gel was transferred to a Hybond-N+ nylon membrane (Amersham Biosciences, Uppsala, Sweden) at 380 rnA for 30 min in O.5x TBE buffer cooled to about 10°e. When the transfer was complete, the DNA was UV crosslinked and the detection of biotin-labeled KB DNA was performed according to the manufacture's procedure. The amount of NF-KB-DNA binding was quantified by densitometric analysis. Band intensity was normalized to unbound probe. NF-KB-DNA binding activity in PBMC derived from an adult healthy donor, stimulated with PHA (5 ug/rnl) was considered 100% and used for normalization. Specificity of binding was determined by addition of 50 and 100 fold excess of unlabeled probe. 
RESULTS
In the present study we tested basal NF-KB-DNA binding activity in PBMC derived from 20 children affected by eczema. The clinical characteristics, IgE serum levels, prick test and NF-KB DNA binding activity of the patients are reported in Table I . For each patient the percentage value reported in Table I represents the average NF-KB-DNA binding activity of a minimum of 2 experiments.
In Fig. I a representative EMSA experiment is shown, which included nuclear extract prepared from unstimulated PBMC of eczema patients and healthy children. Excess cold double strand NF-KB oligonucleotide out-competed NF-KB for DNA binding (lane 4), confirming the specific nature of the binding. The signals for NF-KB-DNA binding corresponding to the patients (lane 5 and 6) were more intense compared to the signals corresponding to controls (lanes 7 and 8) , in which NF-KB-DNA binding was almost undetectable. Nuclear extracts from PBMC derived from an adult healthy donor, left unstimulated (lane 2) and stimulated with PHA for 1 h (lane 3), were used for normalization. NF-KB-DNA binding activity detected in nuclear extracts was significantly higher in PBMC from patients than in PBMC from 9 healthy age-matched controls: 70% (28-302) VS. 40% (12-66), U 28.8; P=0.003 (Fig. 2) .
We then correlated basal NF-KB-DNA binding activity with the SCORAD of eczema patients. Our data showed a positive correlation between NF-KB-DNA binding activity and severity of dermatitis (Pearson's correlation coefficient 0.59; P=0.008) (Fig.  3) . In our cohort no correlation was observed between NF-KB-DNA binding activity and age of the patients, duration of disease and age at the onset.
Additionally, we found a higher average NF-KB-DNA binding activity in non-lgE-mediated eczema children than in IgE-mediated eczema children (82% VS. 49%), if we exclude 1 child (p 17) affected by severe allergy to cow's milk, in which NF-KB-DNA binding activity was 302% (Table I) .
Two out of 3 patients who underwent treatment with intravenous methylprednisolone bolus, showed a prompt improvement of the skin inflammation (p l-SCORAD: before=68 and after=26 and p5-SCORAD: before=25 and after=8), while the third patient failed to respond to the treatment (p20-SCORAD: before=40 and after=48).
For p5 and p20 we had the opportunity to study NF-KB-DNA binding activity both before and 24 hrs after treatment with methylprednisolone bolus. In patient p5 we observed a substantial reduction of the NF-KB-DNA binding after treatment (before=59.l % and after=35.2%), associated with a marked improvement of the clinical picture which was still persisting at 6 months follow up.
On the other hand, patient p20, who did not clinically respond to methylprednisolone bolus, showed no reduction of NF-KB-DNA binding (before=71 % and after=85%). The lower relative position of the NF-KB complex after therapy suggests a different dimer composition and needs further investigation (Fig. 4 ).
DISCUSSION
The crucial role of NF-KB in the transcription of many genes involved in allergic inflammation is well documented and several observations in animal models of asthma (22) (23) (24) and in asthmatic patients have been reported (17, 31) . Nevertheless, no study has been devoted to investigate NF-KB-DNA binding activity in children affected by eczema, and only one report has been published on adult patients on this issue (21 ) .
Here we report, for the first time, a statistically significant increase of NF-KB-DNA binding basal activity in nuclear extracts from PBMC of 20 children affected by chronic eczema, suggesting, for this transcription factor, a role in the pathogenesis of this disease.
lt has been shown that ReI B deficient mice develop skin lesions similar to atopic dermatitis, probably due to impaired IKBa stability (25) and that IKB deficiency in mice results in widespread dermatitis accompanied with sustained NF-KB response (26) . In addition, it was recently demonstrated that mice prone to developing atopic dermatitis display Th2 hyper-responsiveness associated with increased NF-kB-DNA binding activity, and the consequent skin inflammation is reduced by specific NF-KB inhibition (27) . Our observations are consistent with these finding, demonstrating that a significant increase of basal NF-KB-DNA binding activity occurs in PBMC of children affected by chronic eczema and that there is a positive correlation between NF-KB-DNA binding activity and severity of the disease.
These results, taken together, suggest that NF-KB is a key mediator of the skin inflammation in atopic eczema, although, given the redundancy of the NF-KB pathway, it would be relevant, in our patients, to characterize the dimer composition (32) .
Interestingly, we observed that children affected by non-lgE-mediated eczema showed an increased NF-KB activity compared to those affected by IgEmediated eczema. This observation needs more investigation but potentially suggests a lack of positive correlation between NF-KB transcriptional activity and IgE levels.
It is worth recalling that NF-KB is an important regulator of keratinocyte proliferation and differentiation (33) , extending the notion that NF-KB plays a key role in both homeostasis of the epidermis and development of skin appendages. Indeed several studies performed on experimental animal models (34) and on patients affected by primary immune deficiencies with skin abnormalities (35) (36) , suggest that a defect of components of the NF-KB pathway, such as IKKa IKKy(NEMO) or IKBa, might play an important role in skin pathology, also by altering the constitutive structure and biology of the skin (37) . Eczema patients have an increased risk of cutaneous infections by S. aureus, Herpes simplex, molluscum contagiosum and fungi, such as Malassezia furfur (Pityrosporum ovale) and Aspergillus fumigatius (38) (39) (40) (41) (42) . Since these microorganisms can trigger the Toll-like receptor (TLR) pathways, therefore inducing an increase of NF-KB activity, it was important to discriminate, in our study, between allergic inflammation and inflammation induced by pathogens frequently present in the skin lesions of patients affected by eczema. Indeed, a careful clinical examination of our patients was performed to exclude patients showing clinical signs of staphylococcal, fungal and/or herpetic skin lesions, therefore avoiding a bias in the interpretation of the experimental data.
The characterization of the composition of NF-KB dimers bound to the DNA in the PBMC from eczema patients, and the investigation of other molecules upstream NF-KB would be interesting issues; unfortunately the scarcity of the material obtained from our young patients did not allow us to perform these experiments.
Further support for the hypothesis that NF-KB may be important in dermatitis comes from the notion that glucocorticosteroids, the most effective treatment for eczema, are potent inhibitors of these transcription factors (43) (44) . Eczema patients might be refractory to conventional therapies and methylprednisolone bolus has been proposed for their management, although corticosteroid resistance has been occasionally observed (28) . The number of patients treated with this novel protocol is still limited, but it is noteworthy that, in our patients, the success of methylprednisolone bolus therapy correlated with systemic NF-KB-DNA binding activity,
In conclusion, our study may contribute to understanding the basic mechanism of eczema and also aid in designing novel therapeutic strategies targeting NF-KB. A variety of new agents aimed at modulating NF-KB activity is in various stages of investigation (45) (46) , and the identification and targeting of NF-KB subunits critical for disease development could prevent the potential side effects of the inhibition ofNF-KB pathway.
